Cassidy v vroči izmenjavi vpraša Trumpovega kandidata glede preteklih komentarjev o cepivu

WASHINGTON, Senate Health Committee Chair Bill Cassidy (R-La.) confronted Trump nominee Sean Kaufman during a tense confirmation hearing on Wednesday, challenging him over past comments questioning the safety of vaccines. The exchange highlighted growing concerns within Congress about the nominee's stance on public health issues, particularly regarding vaccine trust and pandemic preparedness. Cassidy, a physician specializing in liver disease, accused Kaufman of spreading "damn lies" that undermine public confidence in immunizations. His criticism centered on a now-deleted LinkedIn post, initially reported by STAT, in which Kaufman suggested a link between the hepatitis B vaccine administered at birth and increased autism rates, a claim widely debunked by scientific consensus. The post, which Kaufman described as divisive, was removed for several reasons, including its potential to cause controversy. The confrontation unfolded amid broader scrutiny of Kaufman’s public statements. Earlier reports revealed that the nominee had expressed skepticism toward both mRNA vaccines and the infant hepatitis B shot. During his campaign for a local school board position four years ago, Kaufman also voiced disdain for the Centers for Disease Control and Prevention (CDC). This history became central to Cassidy’s questioning, especially since Kaufman would hold a critical role working alongside the CDC in managing public health crises. Despite these concerns, Kaufman maintained that he supports vaccine safety and efficacy. He cited personal experience, noting that his children had received the hepatitis B vaccine at birth. Additionally, he praised the CDC as “America’s treasure,” emphasizing that his critiques targeted leadership decisions rather than the institution itself. However, he acknowledged limitations in his social media presence, calling the deleted post a misrepresentation of his views. Cassidy, known for opposing aggressive vaccine mandates, warned that he would reject any nominee who doubted vaccine safety or effectiveness. His stance reflects a broader divide within the healthcare sector, particularly with regard to Health and Human Services Secretary Robert F. Kennedy Jr., whose policies have drawn criticism from Cassidy. Their relationship has further strained following Cassidy’s loss in a recent election, partly due to support from Kennedy and former President Donald Trump for his opponent. While much of the hearing focused on Erica Schwartz, the nominee for CDC director, Kaufman remained under intense scrutiny. When asked about his views on mRNA vaccines, he affirmed their safety and effectiveness. However, his position shifted when pressed on whether he supported halting research into mRNA-based vaccine development, a policy proposed by the Department of Health and Human Services. Kaufman argued that prioritizing studies on existing vaccines was more urgent than pursuing new technologies, citing the need to understand adverse effects. Cassidy challenged this reasoning, comparing it to ceasing research on common medications like Aleve due to side effects. Kaufman stood firm, insisting that while he wanted improved mRNA platforms, he believed current efforts should focus on refining existing tools. The debate underscored deepening tensions around how best to balance scientific inquiry with public health priorities. As the hearing concluded, the outcome of Kaufman’s confirmation remains uncertain. His responses, though defensive, failed to fully resolve the committee’s concerns. With the Senate poised to move forward, the episode highlights ongoing debates over vaccine trust, scientific integrity, and the role of government in public health. The final decision will hinge on whether Kaufman can reconcile his past statements with the responsibilities of his future role.